External beam radiotherapy remains the primary treatment modality for localized prostate
cancer. The radiobiology of prostate carcinoma lends itself to hypofractionation, with recent …

Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …

Hypofractionated radical radiotherapy is now an accepted standard of care for tumour sites
such as prostate and breast cancer. Much research effort is being directed towards more …

This is an evidence-based guideline for prostate brachytherapy. Throughout levels of
evidence quoted are those from the Oxford Centre for Evidence based Medicine …

Purpose: The summary presented herein represents Part III of the three-part series
dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing …

Importance Conventional external beam radiotherapy (cEBRT) and stereotactic body
radiotherapy (SBRT) are commonly used treatment options for relieving metastatic bone …

Purpose This is the first report of the 2SMART Phase II trial evaluating the safety of two-
fraction stereotactic ablative radiotherapy (SABR) with focal boost to magnetic resonance …

Purpose The purpose of this study was to highlight the importance of timely brachytherapy
treatment for patients with gynecologic, breast, and prostate malignancies, and provide a …

Following adoption of moderately hypofractionated radiotherapy as a standard for localised
prostate cancer, ultrahypofractioned radiotherapy delivered in five to seven fractions is …

Purpose There is no evidence-based data to guide dose constraints in two-fraction prostate
stereotactic ablative radiotherapy (SABR). Using individual patient-data from two …